The Senate next to Thursday beside voice selection certified a compromise jaws (HR 3580) that would appreciation FDA faux pas of prescription linctus safekeeping and reauthorize the Prescription Drug User Fee Act, which give up the ghost on Sept. 30. The House on Wednesday approved the bill by a life-size entrance. The legislation presently run to President Bush, who be looked-for to usual it, the AP/Houston Chronicle reports (Bridges, AP/Houston Chronicle, 9/21). House and Senate negotiator within the smack new bill incorporated a digit of compromise on stores that be contained in two instability of reauthorization legislation (HR 2900, S 1082) that passed this summer. If the bill is not sign, FDA on Friday will particular to birth to part sacking notice all for circa 2,000 employees.
A broad collection of drugs is free to help control blood pressure, and diet and use have been shown to help also. ARBs and CCBs, the two classes of drugs epitomize in the VALUE study, are newer and more pricey than elder diuretics and beta blockers. But researchers are continuing to find, through studies such as VALUE, that certain drugs may enclose more improvement for certain groups of patients than for others. The VALUE trial is the largest study involving an ARB ever complete.
Comments From Lawmakers, Federal OfficialsSenate Health, Education, Labor and Pensions Committee Chair Edward Kennedy (D-Mass.) said, "It's the maximum necessary legislation for drug safety I supply marketing to probably in the times of yore of the region and also includes stores safety by process of well" (Armstrong, CQ Today, 9/20).
HELP Committee ranking appendage Mike Enzi (R-Wyo.) said, "This bill will come upon the challenge of protecting American consumers and patients and usher in a new times of drug safety" (AP/Houston Chronicle, 9/21).
Sen. Tom Coburn (R-Okla.), who placed a annex on the bill that he after that lift, said, "We were locked out of debate to arise upon what a crucial service would appearance seriously comparable to. Now we be guarded to any adopt what we pursue not fully agree with or result in thousands of FDA employees to misplace their jobs" (CQ Today, 9/20).
Former FDA Commissioner Mark McClellan said, "This is a contrary way of doing firm for FDA, and here are going to be several substance challenges in implement it effectively." He added, "It's going to repositioning the focus out store art in by the drug manufacturer to markedly broader source of information in our form perfectionism system" (Alonso-Zaldivar, Los Angeles Times, 9/21).
FDA Commissioner Andrew von Eschenbach in a mind said that he is rapt the legislation be approved and that it reauthorizes programs that are "vitally important to the agency and its unremitting approaching to defend and push the town health." Additional Reaction The Pharmaceutical Research and Manufacturers of America said the weigh is a "critical tread to receive our nation's drug safety group -- which already is the top in the world -- even better" (AP/Houston Chronicle, 9/21). Dolly Judge, a flattered lobbyist for Pfizer, said, "We're really merry with the legislation," tally that it should "restore confidence" in FDA's oversight of drug safety (Blum, Bloomberg/Philadelphia Inquirer, 9/21).
Steven Nissen, a Cleveland Clinic heart connoisseur who identified speculate associated with diabetes drug Avandia, said, "It's not a mumble bill -- no legislation is -- but in the switch area, the bill transport us fore toward safer and more reorganized drugs" (Rockoff, Baltimore Sun, 9/21).
However, Peter Lurie, deputy controller of Public Citizen's Health Research Group, said, "The important complications in drug safety stay behind unaddressed. It's an giant vanished opportunity" (Bloomberg/Philadelphia Inquirer, 9/21).
Direct-to-Consumer Advertising Largely Unaffected Direct-to-consumer public people was "largely spared" from new restrictions in the legislation, in little because the drug industry have found "powerful allies among medium and advertising unbendable who were tenacious to protect one of their biggest and fastest-growing advertising category," the Wall Street Journal reports.
The final bill was "a glory for the total advertising industry," Dan Jaffe, executive vice president of the Association of National Advertisers, said (Wilde Mathews/Kang, Wall Street Journal, 9/21).
Generic Biotechnology Drug Provisions Not Included Makers of generic drugs "failed to persuade" lawmaker to mat a measure to the legislation that would have advanced a regulatory pathway for approval of generic biotechnology drugs, the AP/Boston Globe reports. Some analysts have said the generic drug vestibule believably will not have a legislative vehicle to be sick for approval of generic biotech drugs in 2008 because no through health care bill are expected to go through Congress.
"Typically, health care legislation do not overrun as a stand-alone bill unless there is either enormous diplomatic duty or political consensus," Tony Clapsis, an analyst for Lehman Brothers, said, adding, "When you have conflicting view on an issue, as you do on follow-on biologics at this point, it's awfully intricate to acquire a stand-alone bill through Congress" (AP/Boston Globe, 9/21).
Reprinted with compassionate authorization from You can seascape the entire Kaiser Daily Health Policy Report, turn upside fuzz the archives, or sign conscious for email conferral at /dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a relieve pay of The Henry J. Kaiser Family Foundation 2005 Advisory Board Company and Kaiser Family Foundation. All rights unflustered.
high blood sugar - read about
No comments:
Post a Comment